(Q45987397)

18 December 2017

title

Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. (English)

1 reference

18 December 2017

1 reference

1 reference

G de L Lopes

1

1 reference

18 December 2017

publication date

1 September 2013

1 reference

18 December 2017

published in

Annals of Oncology

1 reference

18 December 2017

volume

24 Suppl 5

1 reference

18 December 2017

page(s)

v13-6

1 reference

18 December 2017

Projections of global mortality and burden of disease from 2002 to 2030

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

Declining death rates reflect progress against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT323

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT323

1 reference

18 December 2017

1 reference

18 December 2017